ZA200905951B - Reoviruses having modified sequences - Google Patents
Reoviruses having modified sequencesInfo
- Publication number
- ZA200905951B ZA200905951B ZA2009/05951A ZA200905951A ZA200905951B ZA 200905951 B ZA200905951 B ZA 200905951B ZA 2009/05951 A ZA2009/05951 A ZA 2009/05951A ZA 200905951 A ZA200905951 A ZA 200905951A ZA 200905951 B ZA200905951 B ZA 200905951B
- Authority
- ZA
- South Africa
- Prior art keywords
- reoviruses
- modified sequences
- sequences
- modified
- Prior art date
Links
- 241000702244 Orthoreovirus Species 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89442507P | 2007-03-12 | 2007-03-12 | |
| US98956807P | 2007-11-21 | 2007-11-21 | |
| PCT/CA2008/000483 WO2008110004A1 (en) | 2007-03-12 | 2008-03-11 | Reoviruses having modified sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200905951B true ZA200905951B (en) | 2010-11-24 |
Family
ID=39758956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2009/05951A ZA200905951B (en) | 2007-03-12 | 2009-08-27 | Reoviruses having modified sequences |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US7803385B2 (enExample) |
| EP (2) | EP2132315B1 (enExample) |
| JP (1) | JP5577103B2 (enExample) |
| KR (1) | KR101647843B1 (enExample) |
| CN (1) | CN103710359A (enExample) |
| AR (1) | AR066395A1 (enExample) |
| AU (1) | AU2008226291B2 (enExample) |
| CA (1) | CA2678721C (enExample) |
| DK (1) | DK2132315T3 (enExample) |
| ES (1) | ES2548442T3 (enExample) |
| IL (4) | IL200353A (enExample) |
| MX (2) | MX2009009598A (enExample) |
| SG (1) | SG191602A1 (enExample) |
| TW (1) | TW200904979A (enExample) |
| WO (1) | WO2008110004A1 (enExample) |
| ZA (1) | ZA200905951B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| SG191602A1 (en) | 2007-03-12 | 2013-07-31 | Oncolytics Biotech Inc | Reoviruses having modified sequences |
| JP2011500608A (ja) * | 2007-10-22 | 2011-01-06 | オンコリティクス バイオテク，インコーポレーテッド | 増殖性障害の治療レジメン |
| EP2296678A4 (en) * | 2008-05-27 | 2012-03-21 | Oncolytics Biotech Inc | MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION |
| WO2009143611A1 (en) * | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
| BRPI0910185A2 (pt) * | 2008-06-26 | 2015-12-01 | Ceva Sante Animale S A | sorotipo de reovírus aviário isolado, reovírus aviário isolado, peptídeos, vacina, antisoro isolado, anticorpo isolado, método para proteção de aves, método para detecção ou quantificação de reovírus em aves, recipiente para vacinação de aves, kit para vacinação de aves, kit de diagnóstico, linhagem celular derivada da lmh |
| FR2939807B1 (fr) * | 2008-12-11 | 2010-12-17 | Biomerieux Sa | Nouveau reovirus isole, procedes et kits de detection |
| WO2011041789A1 (en) | 2009-10-02 | 2011-04-07 | The Trustees Of Columbia University In The City Of New York | Piscine reovirus immunogenic compositions |
| MX349294B (es) | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| EP2646051A4 (en) * | 2010-12-02 | 2014-05-28 | Oncolytics Biotech Inc | FORMULATIONS OF LIQUID VIRUSES |
| AU2012248082B2 (en) * | 2011-04-29 | 2015-08-20 | Oncolytics Biotech Inc. | Methods of purifying viruses using gel permeation chromatography |
| DK3068411T3 (da) * | 2013-11-15 | 2020-06-22 | Oncolytics Biotech Inc | Oncolytiske vira og forøget cancerbehandlingsregimer |
| US9660989B1 (en) | 2014-01-31 | 2017-05-23 | Google Inc. | Internet-wide identity management widget |
| EP3417866B1 (en) | 2016-02-16 | 2020-12-23 | Osaka University | Medicinal composition for treating fibrosis |
| WO2019237063A1 (en) * | 2018-06-07 | 2019-12-12 | Emory University | Modified reoviruses, particles, and uses in treating proliferative disorders |
| KR102401077B1 (ko) | 2019-01-25 | 2022-05-24 | 바이로큐어 주식회사 | 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| US20220193220A1 (en) * | 2019-05-03 | 2022-06-23 | Kansas State University Research Foundation | Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs |
| US20240041959A1 (en) * | 2020-12-22 | 2024-02-08 | Virocure, Inc. | Novel modified reovirus and use thereof |
| CN116917468A (zh) * | 2020-12-22 | 2023-10-20 | 百洛克株式会社 | 新型修饰的呼肠孤病毒及其用途 |
| US20250154204A1 (en) * | 2021-09-24 | 2025-05-15 | Virocure, Inc. | Novel reovirus-based vaccine platform and use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| TWI289158B (en) | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| NZ524937A (en) * | 2000-11-09 | 2004-10-29 | Oncolytics Biotech Inc | Methods for determining susceptibility of a cell to reovirus infection and for diagnosing proliferative disease treatable with reovirus |
| JP2004519431A (ja) * | 2000-12-01 | 2004-07-02 | ユニバーシティ・オブ・オタワ | 腫瘍溶解性ウイルス |
| IL157304A0 (en) | 2001-03-16 | 2004-02-19 | Oncolytics Biotech Inc | Method of extracting virus from cell culture |
| US7163678B2 (en) * | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
| WO2005111200A1 (en) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Novel strains of reoviruses and methods of uses thereof |
| WO2006001120A1 (ja) * | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | マイナス鎖rnaウイルスを含む抗癌剤 |
| US10260049B2 (en) * | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
| WO2008009115A1 (en) | 2006-07-18 | 2008-01-24 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
| SG191602A1 (en) | 2007-03-12 | 2013-07-31 | Oncolytics Biotech Inc | Reoviruses having modified sequences |
| WO2009143611A1 (en) * | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
| EP2646051A4 (en) * | 2010-12-02 | 2014-05-28 | Oncolytics Biotech Inc | FORMULATIONS OF LIQUID VIRUSES |
| MX349294B (es) * | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
-
2008
- 2008-03-11 SG SG2013040027A patent/SG191602A1/en unknown
- 2008-03-11 CN CN201310353609.2A patent/CN103710359A/zh active Pending
- 2008-03-11 EP EP08733587.3A patent/EP2132315B1/en active Active
- 2008-03-11 MX MX2009009598A patent/MX2009009598A/es active IP Right Grant
- 2008-03-11 EP EP15176066.7A patent/EP2952583A1/en not_active Withdrawn
- 2008-03-11 DK DK08733587.3T patent/DK2132315T3/en active
- 2008-03-11 US US12/046,095 patent/US7803385B2/en active Active
- 2008-03-11 ES ES08733587.3T patent/ES2548442T3/es active Active
- 2008-03-11 KR KR1020097019418A patent/KR101647843B1/ko active Active
- 2008-03-11 JP JP2009552983A patent/JP5577103B2/ja active Active
- 2008-03-11 CA CA2678721A patent/CA2678721C/en active Active
- 2008-03-11 WO PCT/CA2008/000483 patent/WO2008110004A1/en not_active Ceased
- 2008-03-12 TW TW097108636A patent/TW200904979A/zh unknown
- 2008-03-12 AR ARP080101017A patent/AR066395A1/es unknown
- 2008-03-14 AU AU2008226291A patent/AU2008226291B2/en active Active
-
2009
- 2009-08-12 IL IL200353A patent/IL200353A/en active IP Right Grant
- 2009-08-27 ZA ZA2009/05951A patent/ZA200905951B/en unknown
- 2009-09-08 MX MX2013013938A patent/MX346950B/es unknown
-
2010
- 2010-08-02 US US12/848,684 patent/US8691241B2/en active Active
-
2012
- 2012-08-30 IL IL221701A patent/IL221701A0/en unknown
- 2012-08-30 IL IL221702A patent/IL221702A0/en unknown
- 2012-08-30 IL IL221700A patent/IL221700A0/en unknown
-
2014
- 2014-02-13 US US14/179,840 patent/US10039827B2/en active Active
-
2018
- 2018-07-03 US US16/027,206 patent/US10596260B2/en active Active
-
2020
- 2020-02-13 US US16/790,114 patent/US11246930B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL221702A0 (en) | Reoviruses having modified sequences | |
| DE602008005470D1 (en) | Imidazopyridinone | |
| EP2150906A4 (en) | OBJECTS ASSOCIATED WITH A ZONE | |
| AP2010005314A0 (en) | Nanodispersian | |
| GB0723387D0 (en) | Improved dehumldifier | |
| DE602008004135D1 (en) | Triphenylmethan- und xanthenpigmente | |
| GB0808017D0 (en) | shRHA sequences | |
| AU3613P (en) | LS005A01 Leucospermum cuneiforme | |
| AU3606P (en) | Jaywick xTriticosecale | |
| AU3642P (en) | TAS100 Dianella tasmanica | |
| AU3646P (en) | TAS300 Dianella tasmanica | |
| AU3702P (en) | DarwinGold Dianella ensifolia | |
| AU3595P (en) | Goldust Strobilanthes anisophyllus | |
| AU3952P (en) | FLOCHRDEF Chrysocephalum apiculatum | |
| GB0720501D0 (en) | Liquidate | |
| GB0707226D0 (en) | Patent application number one | |
| GB0715962D0 (en) | Time | |
| GB0721702D0 (en) | Hydrogienic globaltechnology limited | |
| GB0701006D0 (en) | Blankie bear | |
| GB0713975D0 (en) | No Riveal | |
| GB0714068D0 (en) | No riveal | |
| GB0721658D0 (en) | My time | |
| GB0700298D0 (en) | Pramstand | |
| AU315538S (en) | Handkechef | |
| AP2007004122A0 (en) | Flashmecash |